Foamix Announces Appointment of Sharon Barbari to Board of Directors
23 janv. 2019 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
21 déc. 2018 07h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
27 nov. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Announces Appointment of Anthony Bruno to Board of Directors
19 nov. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update
07 nov. 2018 16h05 HE
|
Foamix, Ltd.
Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a...
Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
07 nov. 2018 06h00 HE
|
Foamix, Ltd.
FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT,...
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
29 oct. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
12 oct. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
01 oct. 2018 08h00 HE
|
Foamix, Ltd.
Statistically significant improvement demonstrated in reduction of non-inflammatory lesionsDermal tolerability scores consistent with previous Phase 3 studiesRe-analysis including patients from...
Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference
26 sept. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and...